CAV1 and Other metabolic disease: The observed sexual dimorphism does not preclude intestinal epithelial CAV1 as a potential therapeutic target for metabolic disease as many pharmaceuticals currently in use have sexually dimorphic actions, including the LDL cholesterol-lowering drug fenofibrate (Yoon et al., 2002).